Agree with you, @Phaedrus, that the company was juggling too many balls or dealing with too much uncertainty in December. I don’t like the level at which the CR was done, but people also don’t seem to realise or remember how much of a massive as well as crucial turnaround the company went through in the first quarter, in so many different ways. Could there have been less dilution? Perhaps, but I personally believe that the company might have been on its knees without the cap raise, in which case the “adaptation” of the FDA would have been completely futile. Instead, in a quick succession of moves, it got the ship righted.
Hand on heart, as a top 500 shareholder I can say I have applauded the management team’s moves in the last few months.
Agree with you, @Phaedrus, that the company was juggling too...
-
- There are more pages in this discussion • 226 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
-0.050(4.39%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.17 | $1.07 | $8.385M | 7.489M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8500 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 26954 | 3 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |